Company Encyclopedia
View More
name
Ascendis Pharmac
ASND.US
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
1.945 T
ASND.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking61/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE171.66%A
    • Profit Margin-36.03%E
    • Gross Margin89.54%A
  • Growth ScoreA
    • Revenue YoY101.87%A
    • Net Profit YoY44.16%B
    • Total Assets YoY10.89%B
    • Net Assets YoY-87.87%E
  • Cash ScoreC
    • Cash Flow Margin-277.56%D
    • OCF YoY101.87%A
  • Operating ScoreB
    • Turnover0.58B
  • Debt ScoreE
    • Gearing Ratio115.07%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    VP Jensen Files To Sell 10,000 Of Ascendis Pharma A/S [ASND]

    Jensen Michael Wolf, VP of Ascendis Pharma A/S, filed a Form 144 with the SEC on December 4, 2025, to sell 10,000 shares of restricted stock through Merrill Lynch & Co Inc. The sale can occur within 90 days of filing.

    Reuters·
    US
    ASND
    -0.04%
    Reuters·
    US
    ASND
    -0.04%

    VP Singel Files To Sell 218 Of Ascendis Pharma A/S [ASND]

    Singel Stina, Vice President of Ascendis Pharma A/S, filed a Form 144 with the SEC on December 1, 2025, to sell 218 restricted shares through Merrill Lynch & Co Inc. The sale can occur within 90 days of filing.

    Reuters·
    US
    ASND
    -0.04%
    Reuters·
    US
    ASND
    -0.04%

    A Fresh Look at Ascendis Pharma (ASND) Valuation Following FDA Extension for TransCon CNP Review

    Ascendis Pharma's FDA review for TransCon CNP is extended by three months due to new data submission, impacting commercialization timing. Despite this, the stock shows a 54% YTD return, supported by strong trial results. Analysts see a 17.6% undervaluation with a fair value of $257.66, driven by potential product launches and market expansion. Risks include competition and reimbursement delays. The price-to-sales ratio suggests a premium, raising questions about current valuation optimism.

    Simplywall·
    US
    ASND
    -0.04%
    Simplywall·
    US
    ASND
    -0.04%

    European Equities Close Higher in Wednesday Trading; ECB Warns Tariff Exposure Could Strain Banks

    European equities closed higher with Stoxx Europe up 1.06%. The ECB warned that tariff exposure could strain banks but noted the sector's resilience. Novo Nordisk submitted a new drug application to the FDA, boosting its shares by nearly 5%. BioNTech's exchange offer with CureVac was approved, raising its shares by 1.3%. Ascendis Pharma's FDA review for TransCon CNP was extended by three months.

    fidelity·
    US
    NVO
    +0.61%
    US
    BNTX
    +0.13%
    US
    ASND
    -0.04%
    fidelity·
    US
    NVO
    +0.61%
    US
    BNTX
    +0.13%
    US
    ASND
    -0.04%

    European Equities Traded in the US as American Depositary Receipts Surge in Wednesday Trading

    European equities traded in the US as ADRs surged on Wednesday, with the S&P Europe Select ADR Index rising 1.25% to 1,614.11. Notable gainers included Novo Nordisk and Ascendis Pharma, while Cellectis and Anheuser-Busch InBev led decliners. From the UK and Ireland, Akari Therapeutics and NuCana saw significant gains, whereas Autolus Therapeutics and Bicycle Therapeutics experienced declines.

    fidelity·
    US
    ASND
    -0.04%
    US
    NVO
    +0.61%
    fidelity·
    US
    ASND
    -0.04%
    US
    NVO
    +0.61%
    © 2025 Longbridge｜Disclaimer